Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

SEL-201

SKU: orb1225701

Description

SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor with IC5010.8/5.4 nM, respectively; displays acceptable kinome selectivity in the broad KINOMEscan (450 distinct kinases); potently suppresses MNK1/2 activity in a panel of KIT-mutant melanoma cell lines, reduces clonogenicity, migration, and lung metastasis of KIT-mutant melanoma cells both in vitro and in vivo.

Images & Validation

Key Properties

CAS Number2095704-43-9
MW350.806
Purity>98% (HPLC)
FormulaC19H15ClN4O
SMILESC1=CC(=CC(=C1)Cl)CN2C=C(C=CC2=O)C3=CC4=C(C=C3)C(=NN4)N
TargetMNK
Solubility< 1 mg/ml refers to the product slightly soluble or insoluble

Bioactivity

In Vivo
To investigate the pharmacodynamic properties of SLV-2436 (SEL201), 5 consecutive oral doses of 10, 25, and 50 mg/kg are administered to mice every 12 hours (twice-daily schedule). At the 10 mg/kg twice-daily dosage, 4 hours after the fifth administration, a low plasma concentration of 125 ng/mL SLV-2436 is determined. However, dosing at 25 and 50 mg/kg twice daily, equivalent to 50 and 100 mg/kg/d of SLV-2436, yields substantially increased dose-dependent plasma exposure, reaching an average level of 1, 299 ng/mL and 2, 075 ng/mL, respectively. At the 24-hour time point, SLV-2436 is still detectable in the plasma, with dose-dependent concentrations of 9, 73, and 124 ng/mL in the 10, 25, and 50 mg/kg twice-daily treatment groups. Oral (p.o.) administration of SLV-2436 at the dosage of 50 mg/kg twice daily, that is, 100 mg/kg/d, for 37 days is well tolerated in mice.
In Vitro
To confirm the kinome selectivity of SLV-2436 (SEL201), the broad KINOMEscan competitive binding assay is performed at 1 μM, which includes 450 distinct kinases. The observed binding profile for SLV-2436 is significantly concentrated in the CAMK family of kinases that comprises MNK1 and MNK2. SLV-2436-treated KIT-mutant melanoma cells have lower oncogenicity and reduced metastatic ability.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

SLV-2436 | SEL201-88

Similar Products

  • SLV-2436 [orb1302871]

    98.56% (May vary between batches)

    2095704-43-9

    350.8

    C19H15ClN4O

    1 ml x 10 mM (in DMSO), 100 mg, 200 mg, 25 mg, 50 mg, 5 mg, 10 mg, 1 mg, 2 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

SEL-201 (orb1225701)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 190.00
5 mg
$ 290.00
10 mg
$ 460.00
25 mg
$ 860.00
50 mg
$ 1,230.00
100 mg
$ 1,680.00